Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster Françoise Kraeber-Bodéré - Jean-François Chatal

Terms

6Françoise Kraeber-Bodéré
7Jean-François Chatal
6David M Goldenberg
7Alain Faivre-Chauvet
4Loïc Campion
4Chien-Hsing Chang
11Jacques Barbet
4Eric Mirallié

Associations

Freq.WeightAssociation
60.926Françoise Kraeber-Bodéré - Jean-François Chatal
60.926David M Goldenberg - Jean-François Chatal
60.857Alain Faivre-Chauvet - Jean-François Chatal
50.833David M Goldenberg - Françoise Kraeber-Bodéré
40.816Françoise Kraeber-Bodéré - Loïc Campion
40.816Chien-Hsing Chang - David M Goldenberg
70.798Jacques Barbet - Jean-François Chatal
70.798Alain Faivre-Chauvet - Jacques Barbet
50.772Alain Faivre-Chauvet - Françoise Kraeber-Bodéré
50.772Alain Faivre-Chauvet - David M Goldenberg
40.756Jean-François Chatal - Loïc Campion
40.756Eric Mirallié - Jean-François Chatal
40.756Chien-Hsing Chang - Jean-François Chatal
40.756Alain Faivre-Chauvet - Eric Mirallié
30.750Chien-Hsing Chang - Loïc Campion
60.739Françoise Kraeber-Bodéré - Jacques Barbet
60.739David M Goldenberg - Jacques Barbet
30.612Eric Mirallié - Françoise Kraeber-Bodéré
30.612David M Goldenberg - Loïc Campion
30.612David M Goldenberg - Eric Mirallié
30.612Chien-Hsing Chang - Françoise Kraeber-Bodéré
40.603Jacques Barbet - Loïc Campion
40.603Eric Mirallié - Jacques Barbet
40.603Chien-Hsing Chang - Jacques Barbet
30.567Alain Faivre-Chauvet - Loïc Campion
30.567Alain Faivre-Chauvet - Chien-Hsing Chang
20.500Eric Mirallié - Loïc Campion
20.500Chien-Hsing Chang - Eric Mirallié

Documents par ordre de pertinence
000023 (2012) Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
000094 (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
000022 (2012) Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
000095 (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
000116 (2005) Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
000139 (2002) Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
000129 (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
000043 (2011) Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery.
000035 (2011) Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
000063 (2009) Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
000315 (????) Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.

Wicri

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024